Clinical Trial Update: Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin [Phase 2]

View source ↗

Summary

A Phase II study of the combination of oxaliplatin and paclitaxel in metastatic germ cell tumors refractory to cisplatin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor
• Testicular Germ Cell Tumor

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Sanofi | Conditions: Neoplasms, Germ Cell and Embryonal | Phase 2 | Status: COMPLETED